Hospital Israelita Albert Einstein, São Paulo, Brazil.
J Ocul Pharmacol Ther. 2010 Dec;26(6):611-5. doi: 10.1089/jop.2010.0038. Epub 2010 Oct 28.
The aim of this study was to evaluate the change in hyperemia and intraocular pressure (IOP) in patients who switch from prostaglandin or prostamide to a fixed combination of prostamide and timolol maleate.
A multicenter, longitudinal, noncontrolled, nonrandomized open trial was conducted.
One hundred forty-four patients (282 eyes) were selected: 60 (41.6%) were on travaprost, 51 (35.4%) on bimatoprost, and 33 (22.9%) on latanoprost. All patients included were unable to attain adequate IOP control with monotherapy and had no contraindications to β-blockers.
Patients were treated with a fixed combination of bimatoprost and timolol maleate. Hyperemia was evaluated using a referential table, and IOP was measured at 8:00, 12:00, and 16:00 h both before and after 4 months of treatment.
IOP and hyperemia were compared at 2 time points: pretreatment and after 4 months. The mean of the 3 IOP measurements taken at various points during the day was considered for analysis. Generalized estimating equations were used for repeated measures and intereye dependency adjustments.
Hyperemia and IOP were reduced in all 3 groups, with the same pattern for both eyes. The bimatoprost group had the highest levels of hyperemia before treatment when compared with the latanoprost as well as the travaprost group and had the greatest reduction in hyperemia after treatment (P < 0.01). Regarding IOP, all 3 groups had a significant reduction (P < 0.001), but the bimatoprost group had a lower pretreatment IOP when compared with the travaprost and latanoprost groups.
A significant reduction in hyperemia was found after switching from monotherapy with prostaglandins or prostamide to a fixed combination of prostamide and a β-blocker. IOP reduction was significant after the intervention in all 3 groups.
本研究旨在评估从前列腺素或前列腺酰胺类药物转换为前列腺酰胺和马来酸噻吗洛尔固定组合药物的患者的充血和眼压（IOP）变化。
进行了一项多中心、纵向、非对照、非随机开放性试验。
共选择了 144 名患者（282 只眼）：60 名（41.6%）患者使用 travaprost，51 名（35.4%）患者使用 bimatoprost，33 名（22.9%）患者使用 latanoprost。所有入选患者均因单一药物治疗无法达到足够的 IOP 控制且无β受体阻滞剂禁忌证。
患者接受 bimatoprost 和马来酸噻吗洛尔固定组合药物治疗。使用参考表评估充血情况，并在治疗前和治疗后 4 个月的 8：00、12：00 和 16：00 测量 IOP。
在 2 个时间点（治疗前和治疗后 4 个月）比较 IOP 和充血情况。分析时考虑了日间各时间点 3 次 IOP 测量的平均值。使用广义估计方程进行重复测量和双眼相关性调整。
所有 3 组的充血和 IOP 均降低，双眼均呈现相同模式。与 latanoprost 和 travaprost 组相比，bimatoprost 组治疗前的充血程度最高，治疗后充血程度的降低最大（P<0.01）。关于 IOP，所有 3 组均显著降低（P<0.001），但 bimatoprost 组的治疗前 IOP 低于 travaprost 和 latanoprost 组。
从前列腺素或前列腺酰胺类药物的单一疗法转换为前列腺酰胺和β受体阻滞剂的固定组合后，发现充血显著减少。所有 3 组在干预后 IOP 均显著降低。
